<DOC>
	<DOC>NCT02189629</DOC>
	<brief_summary>Multi-center, open-label, non-comparative safety and efficacy study with 52 Weeks of treatment on the face and trunk for acne vulgaris.</brief_summary>
	<brief_title>CD5789 Long Term Safety Study on Acne Vulgaris</brief_title>
	<detailed_description>To determine the safety and efficacy of CD5789 50 Âµg/g cream in the long-term treatment (up to 52 Weeks) of subjects with acne vulgaris. Efficacy will be evaluated as a secondary objective.</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>The Subject has a facial acne severity grade of IGA grade 3 (moderate) at Screening and Baseline visits. The Subject has a minimum of 20 inflammatory lesions and 25 noninflammatory lesions at Screening and Baseline visits on the face. The subject has severe forms of acne (acne conglobata, acne fulminans) or secondary acne form (chloracne, druginduced acne, etc.). The Subject has more than 1 nodule on the face at Screening and at Baseline visits. The Subject has any acne cyst on the face at Screening and at Baseline visits.</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Acne vulgaris</keyword>
	<keyword>Safety</keyword>
	<keyword>Face</keyword>
	<keyword>Trunk</keyword>
</DOC>